Obermatt
See Similar Stocks →

Xencor

NMQ:XNCR · US98401F1057
BiotechnologySmall

360

13
Profit price45
Owner Earnings Yield1
Dividend Yield1
Price/Sales70
Price/Book56
Return on Capital63
Cash Return on Capital58
Return on Equity73
EBIT Margin1
Gross Profitability23
Accruals64
Owner Earnings Margin34
Sales growth8
Profit Growth14
Long-Term EPS Growth1
Reinvestment15
Price momentum30
Debt load33
Refinancing67
Debt Payback1
Liquidity61
Analyst ratings22
Opinion Changes50
Price Target Upside52
Market mood25
Value Creation0/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Xencor doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountryUSA
IndustryBiotechnology
SizeSmall
TypePublic Company
ExchangeNASDAQGM
Founded1997
Employees269
Websitexencor.com
ISINUS98401F1057
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
Chronic DiseasesRheumatologyHematologyNeurologyAllergyInfectious DiseasesGastroenterologyImmunologyOncologyHepatologyBiotechnologyHealth CareTherapeutics

Description

Xencor, Inc. (Xencor) operates as a clinical-stage biopharmaceutical company. The company focuses on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases, who have unmet medical needs. The…

Analysis

Middle-of-the-road

Xencor, Inc. is a middle-of-the-road business: neither the economics nor the price stand out from the peer group.

Valuation data is not available for this company.

The trajectory is tepid and the balance sheet is stretched. The company scores 0/20 on our value-creation score: not creating value.

Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
12
2026

All-time high

37

Mar 2026

All-time low

12

Jun 2026

Average rank

25

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
70
—
—
—
Price/Earnings
30
—
—
—
Price/Book
56
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
33
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Xencor with its peers
Tharimmune
NAQ:THAR
—
CountryUSA
IndustryBiotechnology
SizeX-Small
Full Stock Analysis →
Jade Biosciences
NAQ:JBIO
—
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Aclaris Therapeutics
NSQ:ACRS
28
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Zenas Biopharma
NSQ:ZBIO
42
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Palvella Therapeutics
NAQ:PVLA
100
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
MacroGenics
NSQ:MGNX
24
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →